The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

被引：0
|
作者：
Gonchigdash, Chinbat [1 ]
Purevsuren, Baljinnyam [1 ]
Tungalag, Saruul [1 ]
Tungalagchimeg, Erdenechimeg [1 ]
Norov, Oyundelger [1 ]
机构：
[1] First Cent Hosp Mongolia, Ulaanbaatar, Mongolia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MPN; ruxolitinib; polycythemia vera; hydroxyurea;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-374
引用
收藏
页码：S430 / S430
页数：1
相关论文
共 50 条
  • [21] Ruxolitinib for the Treatment of Polycythemia Vera: Response on Alternative Dose Versus Standard Dose
    Cacciola, Emma
    Vecchio, Veronica
    Cacciola, Elio Gentilini
    Cacciola, Rossella Rosaria
    BLOOD, 2020, 136
  • [22] Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
    Harrison, Claire
    Nangalia, Jyoti
    Boucher, Rebecca H.
    Jackson, Aimee
    Yap, Christina
    O'Sullivan, Jennifer
    Fox, Sonia
    Ailts, Isaak
    Dueck, Amylou C.
    Geyer, Holly L.
    Mesa, Ruben
    Dunn, William
    Nadezhdin, Eugene
    Curto-Garcia, Natalia
    Green, Anna
    Wilkins, Bridget
    Coppell, Jason
    Laurie, John
    Garg, Mamta
    Ewing, Joanne
    Knapper, Steve
    Crowe, Josephine
    Koutsavlis, Ioannis
    Godfrey, Anna L.
    Arami, Siamak
    Drummond, Mark W.
    Byrne, Jennifer
    Clark, Fiona J.
    Mead-Harvey, Carolyn
    Baxter, Joanna E.
    McMullin, Mary Frances
    Mead, Adam J.
    BLOOD, 2022, 140 : 1781 - 1783
  • [23] Ruxolitinib versus best available therapy for PV intolerant or resistant to Hydroxycarbamide a randomised trial
    Harrison, Claire
    Nangalia, Jyoti
    Boucher, Rebecca
    Jackson, Aimee
    Yap, Christina
    O'Sullivan, Jennifer
    Fox, Sonia
    Ailts, Isaak
    Dueck, Amylou
    Geyer, Holly
    Mesa, Ruben
    Dunn, William
    Nadezhdin, Eugene
    Curto-Garcia, Natalia
    Green, Anna
    Wilkins, Bridget
    Coppell, Jason
    Laurie, John
    Garg, Mamta
    Ewing, Joanne
    Knapper, Steven
    Crowe, Josephine
    Chen, Frederick
    Koutsavlis, Ioannis
    Godfrey, Anna
    Arami, Siamak
    Drummond, Mark
    Byrne, Jennifer
    Clark, Fiona
    Mead-Harvey, Carolyn
    Baxter, Elizabeth
    McMullin, Mary Frances
    Mead, Adam
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 88 - 88
  • [24] SAFETY OF RUXOLITINIB IN PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM THE CLINICAL TRIAL PROGRAM
    Verstovsek, S.
    Mesa, R.
    Martino, B.
    Kiladjian, J. -J.
    Jones, M. M.
    He, S.
    Habr, D.
    Alecu, I.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 263 - 264
  • [25] First interim analysis of the German prospective, non-interventional study PaVe: first results on the clinical routine of ruxolitinib in polycythemia vera
    Griesshammer, M.
    von der Heyde, E.
    Weide, R.
    Reichert, D.
    Weniger, J.
    Schlag, R.
    Hutzschenreuter, U.
    Becker, M.
    Just, M.
    Hacker, E.
    Cavanna, D.
    Lengfelder, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 148 - +
  • [26] Negative results of oxygen therapy in polycythemia vera.
    Barach, AL
    McAlpin, KR
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1933, 185 : 178 - 181
  • [27] Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis
    Mikkelsen, Stine Ulrik
    Kjaer, Lasse
    Bjorn, Mads Emil
    Knudsen, Trine Alma
    Sorensen, Anders Lindholm
    Andersen, Christen Bertel Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Pallisgaard, Niels
    Thomassen, Mads
    Skov, Vibe
    Hasselbalch, Hans Carl
    CANCER MEDICINE, 2018, 7 (08): : 3571 - 3581
  • [28] Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Kirito, Keita
    Besses, Carlos
    Hino, Masayuki
    Varela, Ana Ines
    Miller, Carole B.
    Rumi, Elisa
    Rosti, Vittorio
    Blau, Igor Wolfgang
    Mesa, Ruben A.
    Dong, Tuochuan
    Francillard, Nathalie
    Laughlin, Mary
    Vannucchi, Alessandro M.
    BLOOD, 2017, 130
  • [29] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients With Polycythemia Vera
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 4 - 6
  • [30] Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
    Kiladjian, Jean-Jacques
    Zachee, Pierre
    Hino, Masayuki
    Pane, Fabrizio
    Masszi, Tamas
    Harrison, Claire N.
    Mesa, Ruben
    Miller, Carole B.
    Passamonti, Francesco
    Durrant, Simon
    Griesshammer, Martin
    Kirito, Keita
    Besses, Carlos
    Beatriz Moiraghi, Elena
    Rumi, Elisa
    Rosti, Vittorio
    Blau, Igor Wolfgang
    Francillard, Nathalie
    Dong, Tuochuan
    Wroclawska, Monika
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    LANCET HAEMATOLOGY, 2020, 7 (03): : E226 - E237
12345